Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
1997-6-17
pubmed:abstractText
Sulfadoxine/pyrimethamine (Fansidar) is widely used in Africa for treating chloroquine-resistant falciparum malaria. To clarify how parasite resistance to this combination arises, various lines of Plasmodium falciparum were used to investigate the role of naturally occurring mutations in the target enzyme, dihydropteroate synthetase (DHPS), in the parasite response to sulfadoxine inhibition. An improved drug assay was employed to identify a clear correlation between sulfadoxine-resistance levels and the number of DHPS mutations. Moreover, tight linkage was observed between DHPS mutations and high-level resistance in the 16 progeny of a genetic cross between sulfadoxine-sensitive (HB3) and sulfadoxine-resistant (Dd2) parents. However, we also demonstrate a profound influence of exogenous folate on IC50 values, which, under physiological conditions, may have a major role in determining resistance levels. Importantly, this phenotype does not segregate with dhps genotypes in the cross, but shows complete linkage to the two alleles of the dihydrofolate reductase (dhfr) gene inherited from the parental lines. However, in unrelated lines, this folate effect correlates less well with DHFR sequence, indicating that the gene responsible may be closely linked to dhfr, rather than dhfr itself. These results have major implications for the acquisition of Fansidar resistance by malaria parasites.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0950-382X
pubmed:author
pubmed:issnType
Print
pubmed:volume
23
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
979-86
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:9076734-Alleles, pubmed-meshheading:9076734-Animals, pubmed-meshheading:9076734-Antimalarials, pubmed-meshheading:9076734-Dihydropteroate Synthase, pubmed-meshheading:9076734-Drug Antagonism, pubmed-meshheading:9076734-Drug Combinations, pubmed-meshheading:9076734-Drug Resistance, Microbial, pubmed-meshheading:9076734-Folic Acid, pubmed-meshheading:9076734-Genetic Linkage, pubmed-meshheading:9076734-Humans, pubmed-meshheading:9076734-Malaria, Falciparum, pubmed-meshheading:9076734-Microbial Sensitivity Tests, pubmed-meshheading:9076734-Plasmodium falciparum, pubmed-meshheading:9076734-Polymerase Chain Reaction, pubmed-meshheading:9076734-Pyrimethamine, pubmed-meshheading:9076734-Recombination, Genetic, pubmed-meshheading:9076734-Sequence Analysis, DNA, pubmed-meshheading:9076734-Sulfadoxine, pubmed-meshheading:9076734-Tetrahydrofolate Dehydrogenase
pubmed:year
1997
pubmed:articleTitle
Sulfadoxine resistance in the human malaria parasite Plasmodium falciparum is determined by mutations in dihydropteroate synthetase and an additional factor associated with folate utilization.
pubmed:affiliation
Department of Biochemistry and Applied Molecular Biology, University of Manchester Institute of Science and Technology (UMIST), UK.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't